Contains fulltext : 174425.pdf (publisher's version ) (Closed access)Clinical efficacy of antisense oligonucleotides (AONs) for the treatment of neuromuscular disorders depends on efficient cellular uptake and proper intracellular routing to the target. Selection of AONs with highest in vitro efficiencies is usually based on chemical or physical methods for forced cellular delivery. Since these methods largely bypass existing natural mechanisms for membrane passage and intracellular trafficking, spontaneous uptake and distribution of AONs in cells are still poorly understood. Here, we report on the unassisted uptake of naked AONs, so-called gymnosis, in muscle cells in culture. We found that gymnosis works similarly well f...
Contains fulltext : 81075.pdf (publisher's version ) (Closed access)Myotonic dystr...
Introduction: Depending upon the chemistry and annealing target, antisense oligonucleotides can be u...
Brain tissue has become a challenging therapeutic target, in part because of failure of conventional...
Clinical efficacy of antisense oligonucleotides (AONs) for the treatment of neuromuscular disorders ...
Item does not contain fulltextAntisense oligonucleotides (ASOs) are a promising class of therapeutic...
Antisense oligonucleotide therapy is one of the most promising strategies for treatment of myotonic ...
Antisense oligonucleotides (AONs) are being developed as RNA therapeutic molecules for Duchenne musc...
Antisense oligonucleotides (AONs) are being developed as RNA therapeutic molecules for Duchenne musc...
Duchenne muscular dystrophy (DMD) is a severe progressive muscle wasting disorde...
For more than two decades, antisense oligonucleotides (ODNs) have been used to modulate gene express...
Myotonic Dystrophy type 1 (DM1) is a genetic disorder caused by an expansion of a (CTG)n repeat in t...
Delivery of antisense oligonucleotides, AON, presents many of the same challenges as delivery of any...
Neuromuscular disorders such as Duchenne Muscular Dystrophy and Spinal Muscular Atrophy are neurodeg...
ABSTRACT The effects of 15-mer phosphorothioate antisense oligodeoxynucleotides (aODNs) specifically...
We have found that antisense oligonucleotides and siRNA molecules modified with repeat structures of...
Contains fulltext : 81075.pdf (publisher's version ) (Closed access)Myotonic dystr...
Introduction: Depending upon the chemistry and annealing target, antisense oligonucleotides can be u...
Brain tissue has become a challenging therapeutic target, in part because of failure of conventional...
Clinical efficacy of antisense oligonucleotides (AONs) for the treatment of neuromuscular disorders ...
Item does not contain fulltextAntisense oligonucleotides (ASOs) are a promising class of therapeutic...
Antisense oligonucleotide therapy is one of the most promising strategies for treatment of myotonic ...
Antisense oligonucleotides (AONs) are being developed as RNA therapeutic molecules for Duchenne musc...
Antisense oligonucleotides (AONs) are being developed as RNA therapeutic molecules for Duchenne musc...
Duchenne muscular dystrophy (DMD) is a severe progressive muscle wasting disorde...
For more than two decades, antisense oligonucleotides (ODNs) have been used to modulate gene express...
Myotonic Dystrophy type 1 (DM1) is a genetic disorder caused by an expansion of a (CTG)n repeat in t...
Delivery of antisense oligonucleotides, AON, presents many of the same challenges as delivery of any...
Neuromuscular disorders such as Duchenne Muscular Dystrophy and Spinal Muscular Atrophy are neurodeg...
ABSTRACT The effects of 15-mer phosphorothioate antisense oligodeoxynucleotides (aODNs) specifically...
We have found that antisense oligonucleotides and siRNA molecules modified with repeat structures of...
Contains fulltext : 81075.pdf (publisher's version ) (Closed access)Myotonic dystr...
Introduction: Depending upon the chemistry and annealing target, antisense oligonucleotides can be u...
Brain tissue has become a challenging therapeutic target, in part because of failure of conventional...